Upstate Active Clinical Trials

Study Title:

ADCS/Biohaven BHV4157-203: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial
to Evaluate the Efficacy and Safety of BHV-4157 in Patients
with Mild to Moderate Alzheimer’s Disease (T2 PROTECT AD)

What is the purpose of the study?

The purpose of this study is to test the safety, effectiveness and tolerability of the drug BHV-4157 in patients with Alzheimer's disease.

Upstate Institutional Review Board (IRB) Number:

1374750

Study/Protocol ID:

BHV4157-203

Study Phase:

Phase 2

Patient Age Group:

Adults

Principal Investigator:

Sharon A Brangman

What is involved if I participate?

  • How long is the study?
    52 weeks

Where will the study take place?

The Clinical Research Unit, located at the Institute for Human Performance (IHP)

Other Information:

Subjects are compensated for their time to participate in the study ($40 per completed visit).

ClinicalTrials.Gov ID:

NCT03605667

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Colleen A Dillenbeck
Phone: 315-464-5788
Email: dillenco@upstate.edu

Return to Previous Page || Search Again

Top